Novartis: Fundamentals still there, momentum more questionable

BUY, Fair Value CHF107 vs. CHF110 (+20%)
News published on October Wednesday 28, 2015
Share on

Nothing too serious or to be worried about but nothing to be excited about either in the Q3 numbers. This quarterly release leaves us with a mixed taste. Short term, RELAX HF2 is key. Without its support and although the current share price is attractive, we would not make Novartis a short-term BUY.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities